Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Dupilumab for treating Chronic obstructive pulmonary disease (COPD)	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Chronic obstructive pulmonary disease (COPD)	Respiratory System	2022	View \| Download
Dupilumab for treating bullous pemphigoid	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Bullous pemphigoid	Dermatology	2024	View \| Download
Dupilumab for eosinophilic oesophagitis in paediatric patients	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Eosinophilic oesophagitis	Gastroenterology , Immunology	2023	View \| Download
Dupilumab for children aged 6 to less than 12 years with severe atopic dermatitis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Atopic dermatitis	Dermatology	2019	View \| Download
Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Atopic dermatitis	Dermatology	2018	View \| Download
Dulaglutide for Type 2 diabetes	Dulaglutide (LY2189265; Trulicity)	Type 2 diabetes	Endocrine Nutritional and Metabolic Disorders	2021	View \| Download
Dronabinol for muscle spasticity caused by multiple sclerosis	Dronabinol (BX-1; PPP-002; Syndros; Namisol; ECP002A)	Muscle spasticity	Musculoskeletal System , Neurology	2021	View \| Download
Doxecitine and doxribtimine for treating thymidine kinase 2 deficiency	Doxecitine , Doxribtimine	Thymidine kinase 2 deficiency	Genetic Disorders	2024	View \| Download
Dostarlimab with paclitaxel and carboplatin for recurrent or primary advanced endometrial cancer	Carboplatin (Paraplatin) , Dostarlimab (TSR-042; Jemperli) , Paclitaxel (Taxol; paclitaxel albumin)	Endometrial cancer	Female Reproductive Cancer	2023	View \| Download
Dostarlimab with chemotherapy and niraparib for treating advanced epithelial ovarian cancers – first line	Chemotherapy , Dostarlimab (TSR-042; Jemperli) , Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate)	Epithelial ovarian cancers	Female Reproductive Cancer	2023	View \| Download